Pfizer and Mylan to Combine Off-Patent Drugs Businesses
The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
Pfizer Beats Estimates on Strength in Key Drugs
Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
Proposals to Separate Joint CEO-Board Chair Roles Go Nowhere
Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.
Pfizer to Split Into Three Units
The company also announced it would defer drug price hikes, following pressure from President Donald Trump.
Pfizer Q4 Profit Surges to $12B But Shares Fall
The 3% drop in the share price appears to reflect the company's estimate of a 2018 tax rate of 17%, which is higher than investors anticipated.
Generic Competition Hits Pfizer’s Q2 Sales
The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.
Finance Chiefs Praise Deloitte’s CFO Academy
Participants and the CFOs who send them to the program express passion for the development of future finance leaders.
What Makes for a Public-Company CFO?
Five top finance chiefs tell how they got where they are, and what their potential successors need to do.
Pfizer Makes Cancer Play With Medivation Deal
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
Ex-Pfizer Employee Accused of Insider Trading
Michael Maciocio allegedly misused confidential information about potential Pfizer deals to make trades himself and tip off a stockbroker friend.
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.